Test pipeline | AUROBAC THERAPEUTICS

ATX101New Chemical Entity

First-in-class therapeutic targeting the loss of vascular integrity in septic shock

Target indication: Treatment of early septic shock to prevent progression and improve outcome

Partner

ATX401New Biological Entity

First engineered lysin active against multiple clinically-relevant Gram-negative pathogens

Target indication: Treatment of HAP/VAP caused by Gram-negative bacteria as 1^st line therapy suppressing AMR emergence

Partner

ATX2Hit Discovery Program

Internal Drug Discovery Engine to identify new Gram-negative antimicrobial peptides

Target indication: 2^nd line precision treatment of infections caused by Gram-negative pathogens

Partner

ATX3Hit Discovery Collaboration

Drug Discovery Engine to identify novel drug leads of microbial origin

Target indication: 2^nd line precision treatment of infections caused by Gram-negative pathogens

Partner